I thought what happened 25 years ago was a once- in-a-lifetime event… but how wrong I was. Because here we are, a quarter of a century later, almost to the exact day, and it’s happening again.

CRNX Insider Trading

Insider Trading Chart
Insider Trading History
Frequently Asked Questions
About

Insider Ownership Percentage: 6.00%

Insider Buying (Last 12 Months): $0.00

Insider Selling (Last 12 Months): $26,278,027.53

Crinetics Pharmaceuticals Insider Trading History Chart

Crinetics Pharmaceuticals Share Price & Price History

^$56.06

▼ -0.97 (-1.70%)

As of 11/22/2024 01:00 AM ET

Days: 30 | 90 | 365

Watch this before it gets removed

From Porter & Company | Ad

If you missed it, my emergency election broadcast is now available - but will be removed soon

Click here to watch it now.

Crinetics Pharmaceuticals Insider Trading History

Transaction Date	Insider Name	Title	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction
10/3/2024	Dana Pizzuti	Insider	Sell	14,375	$54.63	$785,306.25	28,507
9/26/2024	Marc Wilson	CFO	Sell	25,000	$51.11	$1,277,750.00	111,092
9/10/2024	Stephen F. Betz	Insider	Sell	1,035	$51.50	$53,302.50	68,576
8/26/2024	Stephen F. Betz	Insider	Sell	3,000	$53.19	$159,570.00	69,611
7/25/2024	Marc Wilson	CFO	Sell	19,056	$53.88	$1,026,737.28	111,092
7/25/2024	Stephen F. Betz	Insider	Sell	3,000	$53.43	$160,290.00	75,611
7/15/2024	Jeff E. Knight	COO	Sell	27,000	$55.00	$1,485,000.00	51,653
7/15/2024	Marc Wilson	CFO	Sell	25,000	$55.00	$1,375,000.00	111,092
7/10/2024	Stephen F. Betz	Insider	Sell	3,000	$48.55	$145,650.00	78,611
7/5/2024	James Hassard	Insider	Sell	15,000	$44.08	$661,200.00	29,259
7/3/2024	Dana Pizzuti	Insider	Sell	14,375	$44.87	$645,006.25	28,507
6/28/2024	Marc Wilson	CFO	Sell	32,129	$43.61	$1,401,145.69	111,092
6/26/2024	Jeff E. Knight	COO	Sell	956	$44.38	$42,427.28	52,580
6/24/2024	Dana Pizzuti	Insider	Sell	9,500	$45.73	$434,435.00	27,786
6/21/2024	James Hassard	Insider	Sell	15,000	$44.66	$669,900.00	29,259
6/10/2024	Stephen F. Betz	Insider	Sell	3,000	$43.86	$131,580.00	83,643
5/28/2024	Stephen F. Betz	Insider	Sell	3,000	$47.49	$142,470.00	86,643
5/10/2024	Stephen F. Betz	Insider	Sell	3,000	$49.43	$148,290.00	89,643
5/8/2024	Richard Scott Struthers	CEO	Sell	107,448	$49.40	$5,307,931.20	257,485
4/15/2024	Dana Pizzuti	Insider	Sell	14,375	$44.47	$639,256.25	27,786
4/4/2024	Richard Scott Struthers	CEO	Sell	40,951	$49.17	$2,013,560.67	237,835
3/28/2024	Stephanie Okey	Director	Sell	17,500	$46.38	$811,650.00	6,000
3/22/2024	Jeff E. Knight	COO	Sell	32,359	$44.31	$1,433,827.29	52,580
3/20/2024	Dana Pizzuti	Insider	Sell	15,089	$44.06	$664,821.34	27,786
3/20/2024	Matthew K. Fust	Director	Sell	60,000	$44.14	$2,648,400.00	18,536
3/19/2024	Marc Wilson	CFO	Sell	6,942	$42.91	$297,881.22	110,630
1/25/2024	Stephen F. Betz	Insider	Sell	3,000	$37.26	$111,780.00	73,298
1/10/2024	Stephen F. Betz	Insider	Sell	3,000	$37.65	$112,950.00	76,298
1/3/2024	Dana Pizzuti	Insider	Sell	14,375	$35.00	$503,125.00	5,911
1/2/2024	Marc Wilson	CFO	Sell	10,000	$35.47	$354,700.00	96,055
12/26/2023	Stephen F. Betz	Insider	Sell	3,000	$35.89	$107,670.00	79,298
12/21/2023	Dana Pizzuti	Insider	Sell	9,583	$34.57	$331,284.31	5,911
12/11/2023	Stephen F. Betz	Insider	Sell	3,000	$32.87	$98,610.00	82,298
11/27/2023	Stephen F. Betz	Insider	Sell	3,000	$31.84	$95,520.00	85,298
11/3/2023	Richard Scott Struthers	CEO	Sell	199,082	$30.56	$6,083,945.92	135,522
11/1/2023	Marc Wilson	CFO	Sell	10,000	$28.75	$287,500.00	95,601
10/17/2023	Alan Seth Krasner	Insider	Sell	7,000	$30.00	$210,000.00	43,210
7/13/2023	Richard Scott Struthers	CEO	Sell	14,157	$20.35	$288,094.95	630,805
7/11/2023	Richard Scott Struthers	CEO	Sell	24,384	$20.14	$491,093.76	656,421
6/20/2023	Marc Wilson	CFO	Sell	30,922	$19.97	$617,512.34	95,158
6/16/2023	Richard Scott Struthers	CEO	Sell	50,000	$20.81	$1,040,500.00	680,805
6/8/2023	Coelho Rogerio Vivaldi	Director	Buy	5,000	$22.06	$110,300.00	5,000
4/5/2023	Dana Pizzuti	Insider	Sell	8,212	$16.15	$132,623.80	4,500
1/25/2023	Stephen F. Betz	Insider	Sell	8,336	$21.07	$175,639.52	67,815
1/17/2023	Stephen F. Betz	Insider	Sell	3,126	$18.00	$56,268.00	76,151
12/15/2022	Stephen F. Betz	Insider	Sell	3,126	$16.00	$50,016.00	82,403
12/1/2022	Stephen F. Betz	Insider	Sell	3,126	$17.84	$55,767.84	84,968
11/15/2022	Stephen F. Betz	Insider	Sell	3,126	$18.72	$58,518.72	88,094
10/17/2022	Stephen F. Betz	Insider	Sell	3,126	$17.73	$55,423.98	94,346
10/3/2022	Stephen F. Betz	Insider	Sell	3,126	$19.64	$61,394.64	97,472
9/15/2022	Stephen F. Betz	Insider	Sell	4,168	$21.01	$87,569.68	100,598
9/7/2022	Stephen F. Betz	Insider	Sell	1,042	$21.00	$21,882.00	104,766
7/26/2022	Jeff E. Knight	COO	Sell	1,152	$20.70	$23,846.40	4,950
7/13/2022	Matthew K. Fust	Director	Sell	5,700	$20.96	$119,472.00	12,536
5/2/2022	Stephen F. Betz	Insider	Sell	3,247	$20.10	$65,264.70	107,598
4/18/2022	Perceptive Advisors Llc	Major Shareholder	Buy	157,515	$22.22	$3,499,983.30	5,321,032
4/18/2022	Stephen F. Betz	Insider	Sell	5,664	$25.81	$146,187.84	110,845
4/13/2022	Richard Scott Struthers	CEO	Sell	138,643	$26.83	$3,719,791.69	730,805
4/5/2022	Richard Scott Struthers	CEO	Sell	21,357	$25.34	$541,186.38	57,400
4/4/2022	Stephen F. Betz	Insider	Sell	9,000	$23.97	$215,730.00	116,509
3/31/2022	Stephen F. Betz	Insider	Sell	4,164	$21.06	$87,693.84
3/1/2022	Stephen F. Betz	Insider	Sell	3,123	$19.73	$61,616.79
2/7/2022	Ajay Madan	Insider	Sell	13,411	$17.83	$239,118.13
2/1/2022	Stephen F. Betz	Insider	Sell	3,123	$18.79	$58,681.17
1/18/2022	Stephen F. Betz	Insider	Sell	4,168	$23.29	$97,072.72
1/3/2022	Stephen F. Betz	Insider	Sell	7,168	$28.02	$200,847.36
12/28/2021	Stephen F. Betz	Insider	Sell	3,000	$27.95	$83,850.00
12/15/2021	Stephen F. Betz	Insider	Sell	5,668	$24.14	$136,825.52
12/1/2021	Stephen F. Betz	Insider	Sell	5,668	$27.38	$155,189.84

Watch this before it gets removed

From Porter & Company | Ad

If you missed it, my emergency election broadcast is now available - but will be removed soon

Click here to watch it now.

SEC Filings (Institutional Ownership Changes) for Crinetics Pharmaceuticals (NASDAQ:CRNX)

98.51% of Crinetics Pharmaceuticals stock is owned by institutions. Institutional ownership can be a sign of analyst confidence in the fundamentals of the stock.

Institutional Buying and Selling by Quarter

Crinetics Pharmaceuticals Institutional Trading History

Reporting Date	Hedge Fund	Shares Held	Market Value	% of Portfolio	Quarterly Change in Shares	Ownership in Company
11/16/2024	Geode Capital Management LLC	1,848,133	$94.46M	0.0%	+10.1%	1.993%
11/15/2024	Barclays PLC	207,712	$10.61M	0.0%	+75.5%	0.224%
11/15/2024	Pier Capital LLC	108,361	$5.54M	0.8%	-0.2%	0.117%
11/15/2024	Orion Portfolio Solutions LLC	18,236	$0.93M	0.0%	-4.2%	0.020%
11/15/2024	Castleark Management LLC	73,340	$3.75M	0.2%	N/A	0.079%
11/15/2024	Jane Street Group LLC	129,592	$6.62M	0.0%	-4.1%	0.140%
11/15/2024	Wellington Management Group LLP	4,459,691	$227.89M	0.0%	-3.5%	4.809%
11/15/2024	State Street Corp	2,838,484	$145.05M	0.0%	+0.9%	3.061%
11/15/2024	Stifel Financial Corp	10,038	$0.51M	0.0%	-4.9%	0.011%
11/15/2024	Point72 Asset Management L.P.	2,300,643	$117.56M	0.3%	-17.3%	2.481%
11/15/2024	Parkman Healthcare Partners LLC	77,623	$3.97M	0.5%	-45.1%	0.084%
11/15/2024	Ikarian Capital LLC	426,913	$21.82M	2.9%	-27.5%	0.460%
11/15/2024	Janus Henderson Group PLC	2,429,450	$124.13M	0.1%	-1.1%	2.620%
11/15/2024	HighVista Strategies LLC	28,911	$1.48M	0.5%	-18.0%	0.031%
11/15/2024	Cinctive Capital Management LP	49,445	$2.53M	0.1%	N/A	0.053%
11/14/2024	Vestal Point Capital LP	205,000	$10.48M	0.8%	N/A	0.256%
11/14/2024	Martingale Asset Management L P	22,074	$1.13M	0.0%	N/A	0.028%
11/14/2024	PEAK6 Investments LLC	10,000	$0.51M	0.0%	+25.0%	0.012%
11/14/2024	UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC	271,747	$13.89M	0.0%	+4.1%	0.340%
11/14/2024	Acuta Capital Partners LLC	131,700	$6.73M	5.5%	-2.5%	0.165%
11/13/2024	Glenmede Trust Co. NA	17,144	$0.88M	0.0%	-4.5%	0.021%
11/13/2024	BNP Paribas Financial Markets	20,942	$1.07M	0.0%	+134.2%	0.026%
11/13/2024	Advantage Alpha Capital Partners LP	8,640	$0.44M	0.1%	N/A	0.011%
11/13/2024	FMR LLC	4,455,770	$227.69M	0.0%	+8.8%	5.567%
11/13/2024	The Manufacturers Life Insurance Company	134,087	$6.85M	0.0%	+2.3%	0.168%
11/13/2024	Fisher Asset Management LLC	482,099	$24.64M	0.0%	+8.4%	0.602%
11/12/2024	Algert Global LLC	42,777	$2.19M	0.1%	+2.6%	0.053%
11/12/2024	Valence8 US LP	6,684	$0.34M	0.1%	N/A	0.008%
11/12/2024	Charles Schwab Investment Management Inc.	655,418	$33.49M	0.0%	+9.8%	0.819%
11/9/2024	Intech Investment Management LLC	22,348	$1.14M	0.0%	N/A	0.028%
11/8/2024	BNP PARIBAS ASSET MANAGEMENT Holding S.A.	491,381	$25.11M	0.1%	-10.0%	0.614%
11/8/2024	Advisors Asset Management Inc.	2,806	$0.14M	0.0%	+56.1%	0.004%
11/8/2024	Connor Clark & Lunn Investment Management Ltd.	20,633	$1.05M	0.0%	+2.5%	0.026%
11/8/2024	Jennison Associates LLC	2,793,614	$142.75M	0.1%	+0.5%	3.490%
11/8/2024	Commerce Bank	4,155	$0.21M	0.0%	N/A	0.005%
11/7/2024	First Turn Management LLC	353,376	$18.06M	2.9%	-4.3%	0.441%
11/7/2024	Swiss National Bank	130,900	$6.69M	0.0%	+0.5%	0.164%
11/6/2024	Natixis Advisors LLC	44,346	$2.27M	0.0%	+36.6%	0.055%
11/6/2024	KBC Group NV	2,193	$0.11M	0.0%	+22.8%	0.003%
11/6/2024	Oppenheimer & Co. Inc.	5,469	$0.28M	0.0%	+16.4%	0.007%
11/6/2024	Oppenheimer Asset Management Inc.	4,216	$0.22M	0.0%	N/A	0.005%
11/5/2024	Victory Capital Management Inc.	343,344	$17.55M	0.0%	+51.5%	0.429%
11/4/2024	Lisanti Capital Growth LLC	108,575	$5.55M	1.4%	+30.2%	0.136%
11/4/2024	State of New Jersey Common Pension Fund D	37,341	$1.91M	0.0%	-8.0%	0.047%
11/1/2024	Assetmark Inc.	17,147	$0.88M	0.0%	+13.4%	0.021%
11/1/2024	Fiera Capital Corp	466,075	$23.82M	0.1%	-3.0%	0.582%
11/1/2024	Lewis Asset Management LLC	12,175	$0.62M	0.5%	-1.8%	0.015%
10/31/2024	Principal Financial Group Inc.	77,709	$3.97M	0.0%	+488.5%	0.099%
10/28/2024	US Bancorp DE	11,488	$0.59M	0.0%	+3.4%	0.015%
10/25/2024	China Universal Asset Management Co. Ltd.	15,393	$0.79M	0.1%	+66.1%	0.020%
10/25/2024	abrdn plc	35,467	$1.81M	0.0%	-46.4%	0.045%
10/23/2024	Mirae Asset Global Investments Co. Ltd.	2,895	$0.15M	0.0%	+23.0%	0.004%
10/23/2024	Values First Advisors Inc.	1,644	$84K	0.0%	N/A	0.002%
10/23/2024	Moody Aldrich Partners LLC	139,130	$7.11M	1.3%	-7.4%	0.176%
10/23/2024	Hennion & Walsh Asset Management Inc.	40,835	$2.09M	0.1%	-1.2%	0.052%
10/19/2024	Allspring Global Investments Holdings LLC	1,786	$91K	0.0%	N/A	0.002%
10/11/2024	Creative Planning	19,808	$1.01M	0.0%	+52.4%	0.025%
10/5/2024	Handelsbanken Fonder AB	19,000	$0.97M	0.0%	+15.9%	0.024%
10/3/2024	SG Americas Securities LLC	12,963	$0.66M	0.0%	-83.6%	0.016%
8/20/2024	Novo Holdings A S	1,000,000	$44.79M	2.2%	-9.0%	1.268%
8/20/2024	Senator Investment Group LP	135,000	$6.05M	0.3%	N/A	0.171%
8/19/2024	Point72 Asset Management L.P.	2,780,856	$124.56M	0.3%	-43.8%	3.474%
8/16/2024	Creative Planning	12,997	$0.58M	0.0%	+20.6%	0.016%
8/16/2024	Algert Global LLC	41,707	$1.87M	0.1%	+19.0%	0.053%
8/16/2024	Driehaus Capital Management LLC	6,112,173	$273.76M	2.6%	+17.0%	7.751%
8/15/2024	The Manufacturers Life Insurance Company	131,063	$5.87M	0.0%	+21.7%	0.166%
8/15/2024	Maplelane Capital LLC	160,000	$7.17M	0.2%	N/A	0.203%
8/15/2024	AQR Capital Management LLC	7,126	$0.32M	0.0%	+3.3%	0.009%
8/15/2024	Affinity Asset Advisors LLC	515,000	$23.07M	2.7%	+9.6%	0.653%
8/14/2024	Squarepoint Ops LLC	27,004	$1.21M	0.0%	-21.0%	0.034%
8/14/2024	Point72 Asset Management L.P.	2,780,856	$124.56M	0.3%	-43.8%	3.526%
8/14/2024	First Light Asset Management LLC	1,200,508	$53.77M	4.7%	-29.0%	1.522%
8/14/2024	Marshall Wace LLP	141,204	$6.33M	0.0%	N/A	0.179%
8/14/2024	Farallon Capital Management LLC	497,000	$22.26M	0.1%	+9,840.0%	0.630%
8/14/2024	Xponance Inc.	4,930	$0.22M	0.0%	N/A	0.006%
8/14/2024	Integral Health Asset Management LLC	400,000	$17.92M	1.7%	+23.1%	0.507%
8/14/2024	Hood River Capital Management LLC	410,342	$18.38M	0.4%	N/A	0.520%
8/14/2024	HighVista Strategies LLC	35,237	$1.58M	0.6%	+121.6%	0.045%
8/14/2024	ProShare Advisors LLC	13,704	$0.61M	0.0%	-18.1%	0.017%
8/14/2024	Profund Advisors LLC	21,467	$0.96M	0.0%	-37.4%	0.027%
8/13/2024	Ensign Peak Advisors Inc	616,227	$27.60M	0.1%	-0.8%	0.781%
8/13/2024	Sei Investments Co.	36,973	$1.66M	0.0%	+24.6%	0.047%
8/13/2024	Public Employees Retirement Association of Colorado	9,008	$0.40M	0.0%	-15.5%	0.011%
8/12/2024	Resolute Capital Asset Partners LLC	30,000	$1.34M	0.8%	+50.0%	0.038%
8/12/2024	Seven Eight Capital LP	8,150	$0.37M	0.0%	-60.3%	0.010%
8/12/2024	Hsbc Holdings PLC	10,948	$0.48M	0.0%	+59.2%	0.014%
8/12/2024	Amalgamated Bank	2,692	$0.12M	0.0%	+20.8%	0.003%
8/12/2024	E Fund Management Co. Ltd.	6,813	$0.31M	0.0%	-33.5%	0.009%
8/9/2024	Dimensional Fund Advisors LP	546,759	$24.49M	0.0%	-14.7%	0.693%
8/8/2024	Envestnet Asset Management Inc.	51,791	$2.32M	0.0%	+23.5%	0.066%
8/8/2024	Federated Hermes Inc.	15,768	$0.71M	0.0%	+353.5%	0.020%
8/8/2024	First Turn Management LLC	369,302	$16.54M	2.7%	N/A	0.468%
8/8/2024	Nicholas Investment Partners LP	53,012	$2.37M	0.2%	N/A	0.067%
8/8/2024	American Century Companies Inc.	11,178	$0.50M	0.0%	-11.0%	0.014%
8/8/2024	State of New Jersey Common Pension Fund D	40,599	$1.82M	0.0%	-43.7%	0.051%
8/7/2024	Pier Capital LLC	108,545	$4.86M	0.7%	-6.9%	0.138%
8/6/2024	Quest Partners LLC	934	$42K	0.0%	N/A	0.001%
8/5/2024	Arizona State Retirement System	18,543	$0.83M	0.0%	+5.4%	0.024%
8/5/2024	Victory Capital Management Inc.	226,687	$10.15M	0.0%	-11.8%	0.287%
8/3/2024	TD Asset Management Inc	204,998	$9.18M	0.0%	-12.8%	0.260%

Data available starting January 2016

Crinetics Pharmaceuticals, Inc., a clinical-stage pharmaceutical company, focuses on the discovery, development, and commercialization of novel therapeutics for rare endocrine diseases and endocrine-related tumors. The company's lead product candidate is paltusotine, an oral selective nonpeptide somatostatin receptor type 2 agonist, which is in Phase 3 trial for the treatment of acromegaly; and Phase 2 trial for treating carcinoid syndrome associated with neuroendocrine tumors. It is also developing CRN04894, an investigational oral nonpeptide product candidate to antagonize the adrenocorticotrophic hormone (ACTH) receptor that has completed a Phase 1 study for the treatment of diseases caused by excess ACTH, including congenital adrenal hyperplasia and Cushing's disease. In addition, the company is developing antagonists of the parathyroid hormone (PTH) receptor for the treatment of primary hyperparathyroidism and humoral hypercalcemia of malignancy, and other diseases of excess PTH; identified investigational orally available somatostatin receptor type 3 targeted nonpeptide agonists for the treatment of autosomal dominant polycystic kidney disease; and developing thyroid-stimulating hormone receptor antagonists for the treatment of graves' disease and thyroid eye disease, as well as Oral GLP-1 and GIP nonpeptides for the treatment of diabetes and obesity. Crinetics Pharmaceuticals, Inc. was incorporated in 2008 and is headquartered in San Diego, California.

Today's Range

Now: $56.06

$55.34

$57.10

50 Day Range

MA: $55.32

$49.82

$60.69

52 Week Range

Now: $56.06

$30.50

$62.53

Volume

1,037,121 shs

Average Volume

783,880 shs

Market Capitalization

$5.20 billion

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.62

Who are the company insiders with the largest holdings of Crinetics Pharmaceuticals?: Crinetics Pharmaceuticals' top insider investors include:
Richard Scott Struthers (CEO)
Marc Wilson (CFO)
Stephen F Betz (Insider)
Jeff E Knight (COO)
Alan Seth Krasner (Insider)
James Hassard (Insider)
Dana Pizzuti (Insider)
Matthew K Fust (Director)
Stephanie Okey (Director)
Coelho Rogerio Vivaldi (Director)
Learn More about top insider investors at Crinetics Pharmaceuticals.
Who are the major institutional investors of Crinetics Pharmaceuticals?: Crinetics Pharmaceuticals' top institutional investors include:
Wellington Management Group LLP — 4.81%
FMR LLC — 5.57%
State Street Corp — 3.06%
Jennison Associates LLC — 3.49%
Janus Henderson Group PLC — 2.62%
Point72 Asset Management L.P. — 2.48%
Learn More about top institutional investors of Crinetics Pharmaceuticals stock.
Which institutional investors are selling Crinetics Pharmaceuticals stock?: During the previous quarter, CRNX stock was sold by these institutional investors:
Point72 Asset Management L.P.
Ikarian Capital LLC
Wellington Management Group LLP
SG Americas Securities LLC
Parkman Healthcare Partners LLC
BNP PARIBAS ASSET MANAGEMENT Holding S.A.
abrdn plc
Janus Henderson Group PLC
During the last year, company insiders that have sold Crinetics Pharmaceuticals company stock include:
Richard Scott Struthers (CEO)
Marc Wilson (CFO)
Stephen F Betz (Insider)
Jeff E Knight (COO)
Alan Seth Krasner (Insider)
James Hassard (Insider)
Dana Pizzuti (Insider)
Matthew K Fust (Director)
Learn More investors selling Crinetics Pharmaceuticals stock.
Which institutional investors are buying Crinetics Pharmaceuticals stock?: In the last quarter, CRNX stock was bought by institutional investors including:
FMR LLC
Vestal Point Capital LP
Geode Capital Management LLC
Victory Capital Management Inc.
Barclays PLC
Castleark Management LLC
Principal Financial Group Inc.
Charles Schwab Investment Management Inc.